About Vaishali Pharma Limited

Vaishali Pharma Limited is a public limited company engaged in marketing and trading pharmaceutical products including Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, surgical products, Herbal & Nutraceutical Products, and veterinary supplements for domestic and export markets. The company traces its origins to 1989 and was formally incorporated on April 25, 2008. It was listed on NSE – Emerge on August 22, 2017, and migrated to the NSE Mainboard on January 15, 2020.

Vaishali Pharma has a global presence spanning multiple continents, servicing markets such as Russia, UAE, Madagascar, and Palestine among other emerging economies. It has no subsidiaries but reported an 11.3% equity investment in another company during the year, with no Subsidiary, Joint Venture, or Associate Company as of the report date.

Key Milestones of Vaishali Pharma Limited

• Listing on NSE – Emerge and subsequent migration to NSE Mainboard.
• Equity share sub-division on October 15, 2024.
• 1:1 bonus issue during FY 2024–25 enhancing market accessibility and shareholder base.

Vaishali Pharma Limited Business Segment

Single reportable segment encompassing pharmaceutical APIs, formulations, surgicals, herbal, nutraceuticals, and veterinary supplements.

Operates primarily in pharmaceutical product marketing and trading, serving domestic and international markets with a diversified product range.

Vaishali Pharma Limited Key Management

• Atul Arvind Vasani – Chairman & Managing Director
• Jagruti Atul Vasani – Whole-Time Director
• Dewansh Ajay Vasani – Executive Director & Chief Financial Officer (from May 24, 2025)
• Hemant Damodar Pathak – Chief Executive Officer
• Vishwa Mekhia – Company Secretary Cum Compliance Officer

Latest Updates on Vaishali Pharma Limited

• Completed equity share sub-division and 1:1 bonus issue in FY 2024-25.
• Fully converted 25 lakh share warrants with listing approval pending for issued equity shares and bonus allotments.
• Made an 11.3% equity investment in another company during the year.
• Engaged shareholders for increased borrowing capacity, managerial remuneration, director re-appointments, and amendments to company objects.
• Key board appointments and CFO transition executed in 2025.
• Pending SEBI settlement order on preferential warrant conversion.